Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-2280 in persistent cervical hrHPV infection
NCT06491446Phase 2Completed
- Sponsor
- Antiva Biosciences
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ABI-2280 in human papillomavirus infection (11 cohorts), sponsored by Antiva Biosciences. Primary endpoints: Incidence and Severity of Adverse Events at 24 weeks and Clearance of persistent cervical hrHPV infection at 12 weeks. Started Mar 2024; status: completed.
02
Drugs
ABI-2280
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06491446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491446.